drugset / Trial / NCT04262856
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.
Timeline
- Start
- 2020-05-28
- Primary completion
- 2025-07-09
- Completion
- 2025-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Domvanalimab | Monoclonal antibody | — | Intravenous |
| Subject | Etrumadenant | Small molecule | — | Oral |
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |